Thermo Fisher Scientific (TMO) Receivables (2009 - 2026)

Thermo Fisher Scientific has disclosed Receivables across 18 years of filings, most recently posting $10.9 billion for Q1 2026.

• Quarterly Receivables rose 10.86% year-over-year to $10.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 billion (up 10.86% YoY) and the FY2025 annual result came in at $10.6 billion, up 9.77% from the prior year.
• Receivables rose to $10.9 billion in Q1 2026, from $10.6 billion in the prior quarter.
• Over five years, Receivables peaked at $10.9 billion in Q1 2026 and troughed at $8.9 billion in Q3 2022.
• A 5-year average of $9.7 billion and a median of $9.6 billion in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables jumped 41.59% — and 2024, when it dropped 0.59%.
• Tracing TMO's Receivables over 5 years: stood at $9.4 billion in 2022, then increased by 2.51% to $9.7 billion in 2023, then fell by 0.39% to $9.6 billion in 2024, then grew by 9.77% to $10.6 billion in 2025, then grew by 3.05% to $10.9 billion in 2026.
• Business Quant data shows TMO's Receivables at $10.9 billion in Q1 2026, $10.6 billion in Q4 2025, and $10.5 billion in Q3 2025.